Literature DB >> 29102272

Aspiration Thrombectomy for Treatment of Acute Massive and Submassive Pulmonary Embolism: Initial Single-Center Prospective Experience.

Juan José Ciampi-Dopazo1, Juan María Romeu-Prieto2, Marcelino Sánchez-Casado2, Beatriz Romerosa3, Alfonso Canabal2, María Luisa Rodríguez-Blanco2, Carlos Lanciego4.   

Abstract

PURPOSE: To evaluate the feasibility of aspiration thrombectomy in patients with acute massive or submassive pulmonary embolism (PE).
MATERIALS AND METHODS: This prospective study analyzed patient demographic data, procedural details, and outcomes in 18 consecutive patients (8 men and 10 women; mean age, 60.1 y; range, 36-80 y), 10 with acute submassive PE and 8 with massive PE, treated with an Indigo Continuous Aspiration Mechanical Thrombectomy Catheter between January 2016 and February 2017. Three patients underwent concomitant systemic fibrinolytic treatment with 100 mg tissue plasminogen activator. Technical success was defined as successful placement of devices and initiation of aspiration thrombectomy. Clinical success was defined as stabilization of hemodynamic parameters; improvement in pulmonary hypertension, right heart strain, or both; and survival to hospital discharge. Complications were also analyzed.
RESULTS: The procedure was considered a technical success in 17 patients (94.4%) and a clinical success in 15 (83.3%). Echocardiography showed significant improvements in right ventricle size (46.36 mm ± 2.2 before treatment vs 41.79 mm ± 7.4 after; P = .041), tricuspid annular plane systolic excursion (16 ± 3 before treatment vs 18.57 ± 3.9 after; P = .011), and systolic wave (10 ± 2.1 before treatment vs 13.1 ± 3.8 after; P = .020). Two patients died of massive PE, and 1 died of submassive PE. Two patients who received systemic fibrinolytic agents experienced intracranial bleeding, and abdominal bleeding developed in 1.
CONCLUSIONS: Aspiration thrombectomy is a feasible option for the treatment of acute massive or submassive PE in patients with hemodynamic compromise or right ventricular dysfunction.
Copyright © 2017 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29102272     DOI: 10.1016/j.jvir.2017.08.010

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Catheter directed thrombolytic therapy and aspiration thrombectomy in intermediate pulmonary embolism with long term results.

Authors:  Zoltan Ruzsa; Zoltan Vámosi; Balázs Berta; Balázs Nemes; Károly Tóth; Nándor Kovács; Endre Zima; Dávid Becker; Béla Merkely
Journal:  Cardiol J       Date:  2020-04-24       Impact factor: 2.737

2.  Catheter-Based Therapies Decrease Mortality in Patients With Intermediate and High-Risk Pulmonary Embolism: Evidence From Meta-Analysis of 65,589 Patients.

Authors:  Arkadiusz Pietrasik; Aleksandra Gąsecka; Łukasz Szarpak; Michał Pruc; Tomasz Kopiec; Szymon Darocha; Marta Banaszkiewicz; Maciej Niewada; Marcin Grabowski; Marcin Kurzyna
Journal:  Front Cardiovasc Med       Date:  2022-06-16

Review 3.  Management of Acute Pulmonary Embolism.

Authors:  Connor Tice; Matthew Seigerman; Paul Fiorilli; Steven C Pugliese; Sameer Khandhar; Jay Giri; Taisei Kobayashi
Journal:  Curr Cardiovasc Risk Rep       Date:  2020-10-06

4.  Continuous Aspiration Thrombectomy in High- and Intermediate-High-Risk Pulmonary Embolism in Real-World Clinical Practice.

Authors:  Aleksander Araszkiewicz; Sylwia Sławek-Szmyt; Stanisław Jankiewicz; Bartosz Żabicki; Marek Grygier; Tatiana Mularek-Kubzdela; Zbigniew Krasiński; Maciej Lesiak
Journal:  J Interv Cardiol       Date:  2020-08-21       Impact factor: 2.279

5.  Pulmonary Embolism in Transit Across a Patent Foramen Ovale.

Authors:  Taylor J Manes; Zain Mohiuddin; Michael Bage
Journal:  Cureus       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.